药石科技: 关于提前赎回药石转债的第八次提示性公告

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has announced the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the triggering of conditional redemption clauses, aimed at reducing financial costs and capital expenses [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB on April 20, 2022 [2][3]. - The bonds were listed on the Shenzhen Stock Exchange on May 18, 2022, under the code "123145" [3]. - The conversion period for the bonds is from October 26, 2022, to April 19, 2028 [3]. - The conditional redemption clause was triggered when the stock price exceeded 130% of the conversion price for at least 15 trading days [6][7]. Group 2: Redemption Details - The redemption price is set at 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [8]. - The redemption will occur on September 18, 2025, with trading of the bonds ceasing on September 15, 2025 [9]. - The company will notify bondholders daily leading up to the redemption date and will publish the redemption results within seven trading days after the redemption [9]. Group 3: Conversion Price Adjustments - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 33.61 RMB per share as of May 30, 2025 [5][6]. - The conversion price adjustments are based on the company's stock performance and dividend distributions [4][5].